Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
Makeover sees Viatris move further away from generics
The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.
Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
